Vitiligo - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Vitiligo - Pipeline Review, H2 2016

Vitiligo - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Vitiligo - Pipeline Review, H2 2016
Published Oct 26, 2016
57 pages — Published Oct 26, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo Pipeline Review, H2 2016, provides an overview of the Vitiligo (Dermatology) pipeline landscape.

Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vitiligo Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively for Vitiligo.

Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potent

  
Source:
Document ID
GMDHC8592IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Vitiligo Overview61
Therapeutics Development71
  Pipeline Products for Vitiligo Overview71
Vitiligo Therapeutics under Development by Companies81
Vitiligo Pipeline Products Glance92
  Clinical Stage Products91
  Early Stage Products101
Vitiligo Products under Development by Companies111
Vitiligo Companies Involved in Therapeutics Development124
  Ache Laboratorios Farmaceuticos S/A121
  Biocon Limited131
  Bristol-Myers Squibb Company141
  Clinuvel Pharmaceuticals Limited151
Vitiligo Therapeutics Assessment169
  Assessment by Monotherapy Products161
  Assessment by Target172
  Assessment by Mechanism of Action192
  Assessment by Route of Administration212
  Assessment by Molecule Type232
Drug Profiles2517
  abatacept Drug Profile255
  ACH-24 Drug Profile301
  afamelanotide Drug Profile318
  itolizumab Drug Profile392
  VLRX-001 Drug Profile411
Vitiligo Dormant Projects421
Vitiligo Product Development Milestones4313
  Featured News &Press Releases431
    Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study431
    Dec 03, 2015: Update on North American vitiligo program for SCENESSE441
    May 05, 2015: Clinuvel announces innovative melanocortin for new indications451
    Mar 20, 2015: SCENESSE vitiligo data presented at world s largest dermatology conference461
    Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology471
    May 06, 2014: Clinuvel s Phase II vitiligo study commences in Singapore481
    Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology481
    Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore491
    Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients501
    Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference511
    Dec 19, 2012: Clinuvel Pharma Announces Results From Phase IIa Pilot Study Of Scenesse In Vitiligo512
    Oct 16, 2012: Observations from Clinuvels US vitiligo study published531
    Mar 15, 2012: Observations from Clinuvels vitiligo and EPP programs being presented at the531
    Mar 02, 2011: Clinuvel Announces FDA Approval For Vitiligo Drug Trial542
Appendix562
  Methodology561
  Coverage561
  Secondary Research561
  Primary Research561
  Expert Panel Validation561
  Contact Us561
  Disclaimer571

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Vitiligo - Pipeline Review, H2 2016" Oct 26, 2016. Alacra Store. May 04, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Vitiligo-Pipeline-Review-H2-2016-2088-16707>
  
APA:
Global Markets Direct - Market Research. (2016). Vitiligo - Pipeline Review, H2 2016 Oct 26, 2016. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Vitiligo-Pipeline-Review-H2-2016-2088-16707>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.